These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16100231)

  • 21. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.
    Adamcova M; Sterba M; Simunek T; Potacova A; Popelova O; Mazurova Y; Gersl V
    Expert Opin Drug Saf; 2005 May; 4(3):457-72. PubMed ID: 15934853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors.
    Ehrhardt MJ; Armenian SH; Fulbright JM
    Future Oncol; 2015; 11(14):2031-4. PubMed ID: 26198832
    [No Abstract]   [Full Text] [Related]  

  • 23. Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification.
    de Antonio M; Lupón J; Galán A; Vila J; Zamora E; Urrutia A; Díez C; Coll R; Altimir S; Bayes-Genis A
    Clin Chim Acta; 2013 Nov; 426():18-24. PubMed ID: 23978483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and significance of detectable troponins as measured by highly sensitive assays in the general population.
    de Lemos JA; deFilippi CR
    Coron Artery Dis; 2013 Dec; 24(8):705-9. PubMed ID: 24201087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Troponins in prediction of cardiotoxic effects.
    Auner HW; Tinchon C; Quehenberger F; Linkesch W; Sill H
    Lancet; 2001 Mar; 357(9258):808. PubMed ID: 11254006
    [No Abstract]   [Full Text] [Related]  

  • 26. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients.
    Kanwar M; Hashem M; Rosman H; Kamalakannan D; Cheema A; Ali A; Gardin J; Maciejko JJ
    Am J Cardiol; 2006 Nov; 98(9):1283-7. PubMed ID: 17056347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy.
    Urbanová D; Urban L; Carter A; Maasova D; Mladosievicova B
    Neoplasma; 2006; 53(3):183-90. PubMed ID: 16652186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
    Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
    J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
    Horacek JM; Tichy M; Jebavy L; Pudil R; Ulrychova M; Maly J
    Exp Oncol; 2008 Jun; 30(2):157-9. PubMed ID: 18566582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers in paediatric heart failure: is there value?
    Lin KY
    Cardiol Young; 2015 Dec; 25(8):1469-72. PubMed ID: 26675592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The use of cardiac troponins (T or I) measurement in cardiology and various clinical settings].
    Berroëta C; Provenchère S; Mongredien A; Lasocki S; Benessiano J; Dehoux M; Philip I
    Ann Fr Anesth Reanim; 2006 Oct; 25(10):1053-63. PubMed ID: 16019183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Troponin elevation--differential diagnostic considerations and prognostic importance].
    Jensen JK; Mickley H
    Ugeskr Laeger; 2003 Apr; 165(15):1541-5. PubMed ID: 12715654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstructive cardiomyopathy with persistent marked elevation of troponin T in myasthenia gravis.
    Leone S; Mancuso A; La Fata B; Camarda P; Di Giovanni G; Pasta F; Mancuso L
    Int J Cardiol; 2016 Jan; 203():128-30. PubMed ID: 26512824
    [No Abstract]   [Full Text] [Related]  

  • 36. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.
    Tonkin AM; Blankenberg S; Kirby A; Zeller T; Colquhoun DM; Funke-Kaiser A; Hague W; Hunt D; Keech AC; Nestel P; Stewart R; Sullivan DR; Thompson PL; West M; White HD; Simes J;
    Int J Cardiol; 2015 Dec; 201():499-507. PubMed ID: 26318511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac troponins in renal failure - time for an optimistic consensus?
    Buhaescu I; Izzedine H; Covic A
    Int J Clin Pract; 2005 Nov; 59(11):1317-25. PubMed ID: 16236087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 39. A green light for troponin T in the cardiovascular risk stratification of continuous ambulatory peritoneal dialysis patients?
    Zoccali C; Mallamaci F
    Kidney Int; 2006 Aug; 70(3):408-10. PubMed ID: 16871251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MY APPROACH to low-level troponin elevations.
    Mueller CE
    Trends Cardiovasc Med; 2015 May; 25(4):373. PubMed ID: 25820092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.